BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
See today's BioWorld
Home
» Roche to take IONIS-HTTRx pivotal 'quickly' following early efficacy signal in HD
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Roche to take IONIS-HTTRx pivotal 'quickly' following early efficacy signal in HD
March 5, 2018
By
Marie Powers
No Comments
Stanley Crooke, chairman and CEO of Ionis Pharmaceuticals Inc., was buoyant on a conference call Friday as the company reported details from the phase I/II study of IONIS-HTTRx (RG-6042) in individuals with Huntington's disease (HD).
BioWorld
